Stanford Cures Type 1 Diabetes in Mice for 6 Months

Imagine never needing daily insulin injections again. Stanford Medicine researchers just brought that possibility closer to reality by curing Type 1 diabetes in mice using a combined transplant technique that retrains the immune system itself.

The team, led by Dr. Seung K. Kim at Stanford's Diabetes Research Center, reversed the disease in every single mouse they treated. All 19 animals that received the preventive treatment stayed diabetes-free, and nine mice with long-standing diabetes were completely cured.

Type 1 diabetes happens when the immune system mistakenly attacks insulin-producing cells in the pancreas. People with the disease must carefully monitor their blood sugar and take insulin for their entire lives. About 1.6 million Americans live with Type 1 diabetes today.

The Stanford approach solves two problems at once. Researchers transplanted blood stem cells alongside insulin-producing pancreatic cells from a donor with a different immune profile. This created a hybrid immune system in the mice that combined cells from both the donor and the recipient.

The result? The animals' immune systems stopped attacking their own insulin-producing cells. The transplanted cells began producing insulin normally. Best of all, none of the mice developed dangerous complications, needed insulin injections, or required immune suppression drugs for the full six months of the study.

The work builds directly on research from 2022, when the same team reversed chemically induced diabetes in mice. But this new study tackled the harder challenge of autoimmune diabetes, which more closely mirrors what happens in people with Type 1 diabetes.

Graduate student Preksha Bhagchandani, the study's lead author, and her colleagues added a drug already used to treat autoimmune diseases to the preparation regimen. That simple addition made the difference in preparing the mice for successful transplants.

Why This Inspires

What makes this discovery especially hopeful is how close it already sits to real-world medical practice. The antibodies, drugs, and low-dose radiation the researchers used are already approved and regularly used in clinics for blood stem cell transplants.

The technique grew from decades of work by the late Dr. Samuel Strober and Dr. Judith Shizuru, who showed that bone marrow transplants from partially matched donors could allow kidney transplant patients to keep their new organs functioning for decades without rejection drugs.

Dr. Kim believes the approach could help not just people with Type 1 diabetes but also those with other autoimmune diseases and anyone needing organ transplants. Creating a hybrid immune system that accepts both the recipient's own cells and donated cells could revolutionize transplant medicine.

The research team is now working toward human clinical trials. While moving from mice to people always requires careful steps, the fact that every component of this treatment already exists in medical practice suggests the path forward may be faster than usual.

For millions managing Type 1 diabetes every single day, this research offers something powerful: a future where the disease might be not just managed, but cured.